SciTech Development Expands Leadership Team with Key Appointments to Enhance Oncology Innovations
Advancing Oncology: New Faces at SciTech Development
In a significant move for the oncology sector, SciTech Development, Inc., a clinical-stage company focused on nanotechnology-enabled cancer therapeutics, has made headlines with the appointments of Dr. Peter Littrup as Medical Director for Solid Tumors and Joseph Kraus to its Advisory Board. These additions mark a strategic step as the company progresses in its Series A financing and expands its clinical trials into various cancer types.
Meet Dr. Peter Littrup
Dr. Littrup is a well-respected pioneer in interventional oncology with over three decades of experience in radiology and cancer treatment. Before joining SciTech Development, he served as the Director of Image-Guided Therapies at the Karmanos Cancer Institute and held professorships at Wayne State University and the University of Rochester. With more than 50 patents and over 130 scientific publications to his name, Dr. Littrup is recognized as a thought leader in minimally invasive cancer treatments.
Role and Impact
At SciTech, Dr. Littrup will be instrumental in shaping the clinical strategy and trial designs for the company’s lead therapeutic candidate, ST-001 nanoFenretinide™. This innovative treatment is geared towards solid tumors, and his expertise is expected to significantly broaden its application. According to Earle Holsapple, the CEO of SciTech Development, Dr. Littrup’s extensive understanding of translational oncology will help accelerate the company’s clinical roadmap and unlock greater therapeutic potential for their platform.
Introducing Joseph Kraus
Joining him in this leadership expansion is Joseph Kraus, who has served as the Vice President of Legal at Johnstone Supply—a national distribution company that boasts a revenue of $4 billion. Kraus’s role involves overseeing critical aspects like corporate governance and mergers and acquisitions, making him a valuable asset for SciTech as it navigates its growth phase.
Strategic Contributions
Mr. Kraus’s legal acumen will be vital as SciTech seeks to enhance its corporate structure and financing strategies during the ongoing Series A funding and clinical trials expansion. Andrew Stumpf, SciTech's CFO, emphasized that Mr. Kraus's experience in complex legal frameworks will bolster the company’s growth objectives, enhancing investor confidence in the organization.
A Commitment to Innovation
The leadership moves underscore SciTech Development's steadfast commitment to innovation in oncology. With both medical and legal expertise brought into the leadership fold, it is clear that the company is keen on accelerating the development of ST-001 nanoFenretinide™, a first-in-class therapeutic making waves in the realm of non-Hodgkin lymphoma and set for trials in small-cell lung cancer. This therapeutic candidate has shown promising safety and efficacy results, raising hopes for more effective cancer treatment solutions.
Through this strategic enhancement of its leadership team, SciTech Development is laying a robust foundation for future advancements in cancer therapies, making it a company to watch in the ever-evolving landscape of oncology.
For more detailed information about their innovative efforts, visit SciTech Development's website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.